Clinical trials
Pulmonary Fibrosis clinical trials
Below are recruiting pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06125327RecruitingPhase 2/Phase 3
SC1011 for idiopathic pulmonary fibrosis (IPF)
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Beijing, Beijing MunicipalityAges 40–80 - NCT05571059RecruitingPhase 2
Oral ifetroban for idiopathic pulmonary fibrosis
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
La Mesa, CaliforniaAges 40 years+ - NCT04160715Recruiting
Registry for people with idiopathic pulmonary fibrosis in Korea
This study is a registry that collects health information from people diagnosed with idiopathic pulmonary fibrosis (IPF). It may help researchers better understand IPF and how it changes over time, even if it doesn’t involve a new medication.
Seongnam-siAges 30–100 - NCT00373841Recruiting
Study of genetic and protein changes in idiopathic pulmonary fibrosis
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07687459RecruitingPhase 3
Oral treatment for idiopathic pulmonary fibrosis
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
Hefei, AnhuiAges 40 years+ - NCT06940531Recruiting
Tracking causes of lung flare-ups in cystic fibrosis
This study aims to understand what causes and increases the risk of lung infections (exacerbations) in people with cystic fibrosis. It involves regular monitoring and sample collection at home and in the clinic to identify early warning signs.
Manchester, ManchesterAges 5 years+ - NCT00001532Recruiting
How Genes Affect Lung Disease Development
This research study examines how genetic factors contribute to various lung diseases, including alpha-1 antitrypsin deficiency, cystic fibrosis, and chronic obstructive pulmonary disease. Researchers want to understand why some people develop lung disease and how genetics plays a role, which may help improve treatment in the future.
Bethesda, MarylandAges 2–90 - NCT07761377Recruiting
Using AI to spot lung scarring on CT scans
This study tests whether an AI tool can correctly find lung scarring (pulmonary fibrosis) on CT scans as well as doctors do. The results could lead to faster, more consistent detection of this condition.
TaichungAges 20 years+ - NCT07312305Recruiting
Small airways test in idiopathic pulmonary fibrosis
This study measures how well the small airways in your lungs work if you have idiopathic pulmonary fibrosis (IPF). It aims to find better ways to assess the disease and could lead to improved care.
Milan, LombardyAges 18 years+ - NCT07269262Recruiting
Support program for PPF patients and their caregivers
This study tests a support program for people with progressive pulmonary fibrosis and their caregivers. It focuses on helping both the patient and the person who helps care for them.
Charleston, South CarolinaAges 18 years+ - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Birmingham, AlabamaAges 18 years+ - NCT05674994RecruitingPhase 3
Steroid versus placebo for sudden worsening of lung scarring
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
AngersAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT07683728Recruiting
Observational study of progressive pulmonary fibrosis (PPF) in China
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
BeijingAges Any age - NCT05548283RecruitingPhase 4
Standard IV antibiotic timing for cystic fibrosis lung flare-ups
This study standardizes how IV aminoglycoside antibiotics are given during a 14-day treatment for cystic fibrosis (CF) lung flare-ups. It may help make treatment more consistent and easier to manage for people who need IV antibiotics.
Birmingham, AlabamaAges 6 years+ - NCT05098717Recruiting
PEEP settings guided by lung pressure in pulmonary fibrosis
This trial tests whether using lung-pressure measurements to adjust ventilator PEEP (a breathing-support setting that keeps airways open) can help people with pulmonary fibrosis who are on a breathing machine for acute respiratory failure. It may improve breathing comfort and oxygenation by finding the best PEEP level for you.
ModenaAges 18–90 - NCT04965298RecruitingPhase 3
Lansoprazole add-on treatment for idiopathic pulmonary fibrosis
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Norwich, NorfolkAges 40 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Birmingham, AlabamaAges 21 years+ - NCT04157361Recruiting
Non-invasive lung testing in asthma and cystic fibrosis
This trial studies how well a non-invasive lung test can show lung involvement in people with asthma (especially IgE-related asthma) and people with cystic fibrosis. You might benefit by getting extra lung assessments without invasive procedures.
OlomoucAges Any age - NCT02852928Recruiting
ChILD-EU registry for childhood lung disease samples
This trial builds a European “registry and biobank” of children with suspected or confirmed interstitial lung disease (a type of lung problem), as well as conditions that can look similar. It helps researchers learn more about these rare childhood lung diseases and connect families to future studies.
Hanover, Lower SaxonyAges Any age - NCT05121779RecruitingPhase 1
PET-CT scan compares two tests for lung scarring
This early (Phase 1) study compares two types of PET-CT scans to see how well they detect and measure lung scarring (pulmonary fibrosis). It may help doctors choose the best scan test for diagnosis in the future.
Beijing, Beijing MunicipalityAges 18–80 - NCT07484607Recruiting
Study on infections and treatments in cystic fibrosis exacerbations
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
CardiffAges 16 years+
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary fibrosis?
- Yes. Clin2 currently lists 138 recruiting pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.